-
公开(公告)号:US20100016250A1
公开(公告)日:2010-01-21
申请号:US12297211
申请日:2007-04-13
申请人: Hiroyuki Nagata , Michio Ichimura , Rieko Nakatsu , Shun-Ichi Ikeda , Ayako Kawabata , Toshio Ota , Masayuki Abe , Michio Takashima , Makoto Suzuki
发明人: Hiroyuki Nagata , Michio Ichimura , Rieko Nakatsu , Shun-Ichi Ikeda , Ayako Kawabata , Toshio Ota , Masayuki Abe , Michio Takashima , Makoto Suzuki
IPC分类号: A61K31/7064 , C12P19/30 , C12P19/32 , C12N1/20 , A61K31/7076 , C07H19/20 , C07H19/10 , A61P31/00 , A61K31/7072 , C07H19/24 , A61K31/708 , A61P37/04 , A61P25/00
CPC分类号: C07H19/20 , C07H19/10 , C12N15/117 , C12N2310/17 , C12N2310/351 , C12P19/30
摘要: The present invention provides TLR9 agonists comprising, as an active ingredient, a compound represented by formula (I): (wherein a represents 0 or 1; n represents an integer of 0 to 2; m represents an integer of 0 to 5; X1 and X2 each independently represent a hydrogen atom or hydroxy; Y represents an oxygen atom or a sulfur atom; -Q1-represents —O— or the like; -Q2- represents —O— or the like; -Z- represents —O— or the like; R1, R3 and R4 each independently represent hydroxy or the like; R2 and R5 each independently represent a hydrogen atom, hydroxy or the like; and A represents 6-aminopurin-9-yl or the like) or a pharmaceutically acceptable salt thereof, and the like.
摘要翻译: 本发明提供TLR9激动剂,其包含作为活性成分的由式(I)表示的化合物:(其中a表示0或1; n表示0〜2的整数; m表示0〜5的整数; X1和 X2各自独立地表示氢原子或羟基; Y表示氧原子或硫原子; -Q1表示-O-等; -Q2-表示-O-等; -Z-表示-O-或 类似物; R 1,R 3和R 4各自独立地表示羟基等; R 2和R 5各自独立地表示氢原子,羟基等; A表示6-氨基嘌呤-9-基等)或药学上可接受的盐 等等。
-
公开(公告)号:US5952355A
公开(公告)日:1999-09-14
申请号:US757080
申请日:1996-11-26
申请人: Shun-Ichi Ikeda , Uichiro Kimura , Tadashi Ashizawa , Katsushige Gomi , Hiromitsu Saito , Masaji Kasai , Junji Kanazawa , Kimihito Sasaki , Etsuko Nukui , Masami Okabe , Soichiro Sato
发明人: Shun-Ichi Ikeda , Uichiro Kimura , Tadashi Ashizawa , Katsushige Gomi , Hiromitsu Saito , Masaji Kasai , Junji Kanazawa , Kimihito Sasaki , Etsuko Nukui , Masami Okabe , Soichiro Sato
IPC分类号: C07D209/12 , C07D209/30 , C07D401/06 , C07D405/06 , C07F7/08 , C07H15/24 , A61K31/40 , A61K31/44 , C07D209/32 , C07D209/40
CPC分类号: C07D401/06 , C07D209/12 , C07D209/30 , C07D405/06 , C07F7/0812 , C07H15/24
摘要: The present invention relates to propenone derivatives represented by the following formula (I): ##STR1## wherein R.sup.1 represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, or YR.sup.5 (wherein Y represents S or O; and R.sup.5 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or a substituted or unsubstituted cyclic ether residue); R.sup.2 and R.sup.3 independently represent hydrogen, lower alkyl, or substituted or unsubstituted aralkyl, or alternatively R.sup.2 and R.sup.3 are combined to form substituted or unsubstituted methylene or ethylene; R.sup.4 represents hydrogen, hydroxy, lower alkyl, substituted or unsubstituted aralkyl, lower alkoxy, substituted or unsubstituted aralkyloxy, or halogen; and X represents substituted or unsubstituted indolyl; or pharmaceutically acceptable salts thereof.
摘要翻译: 本发明涉及由下式(I)表示的丙烯酮衍生物:其中R1表示氢,取代或未取代的低级烷基,取代或未取代的芳基或YR5(其中Y表示S或O; R5表示取代或未取代的低级烷基 取代或未取代的芳基,取代或未取代的杂芳基,或取代或未取代的环醚残基); R2和R3独立地表示氢,低级烷基或取代或未取代的芳烷基,或者R2和R3组合形成取代或未取代的亚甲基或亚乙基; R4表示氢,羟基,低级烷基,取代或未取代的芳烷基,低级烷氧基,取代或未取代的芳烷氧基或卤素; X表示取代或未取代的吲哚基; 或其药学上可接受的盐。
-